Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900900 · ClinicalTrials.gov registry record · Phase 2
The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers
A Phase 2 study, sponsored by Jed E. Rose.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00900900 is a Phase 2 study that has completed, run by Jed E. Rose. The registered enrollment target is 22 participants.
The verdict
NCT00900900, a Phase 2 study, has completed, sponsored by Jed E. Rose.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will evaluate the potential therapeutic value of two neurosteroid treatments (DHEA and pregnenolone) in the treatment of tobacco withdrawal symptoms. This will include assessing whether these agents relieve craving for cigarettes elicited by exposure to a mildly stressful cognitive task. Pregnenolone (400 mg orally), DHEA (400 mg orally) and placebo will be administered one at each of the three sessions in a randomized order.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT pregnenolone
- DIETARY_SUPPLEMENT dehydroepiandrosterone (DHEA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00900900
The ClinicalTrials.gov registry entry for NCT00900900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jed E. Rose, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00900900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00900900 about?
NCT00900900 is a clinical study titled "The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers". This study will evaluate the potential therapeutic value of two neurosteroid treatments (DHEA and pregnenolone) in the treatment of tobacco withdrawal symptoms. This will include assessing whether these agents relieve craving for cigarettes elicited by exposure to a mildly stressful cognitive task. ...
What is the current status of trial NCT00900900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2009-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00900900?
The interventions under investigation include: Placebo (DRUG), pregnenolone (DIETARY_SUPPLEMENT), dehydroepiandrosterone (DHEA) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00900900?
This trial is sponsored by Jed E. Rose, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.